Silence Therapeutics (Silence Therapeutics) EPS (Diluted) : $-0.49 (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Silence Therapeutics EPS (Diluted)?

Silence Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.16. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.49.

Silence Therapeutics's EPS (Basic) for the three months ended in Dec. 2023 was $-0.16. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.49.

Silence Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was $-0.16. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.49.

During the past 3 years, the average EPS without NRIGrowth Rate was 3.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was -9.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was -10.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Silence Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 53.60% per year. The lowest was -39.30% per year. And the median was 3.70% per year.

Silence Therapeutics EPS (Diluted) Historical Data

The historical data trend for Silence Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics EPS (Diluted) Chart

Silence Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-0.34

-0.54

-0.59

-0.51

-0.49

Silence Therapeutics Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial															-0.16	-0.12	-0.12	-0.09	-0.16

Competitive Comparison of Silence Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, Silence Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silence Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's PE Ratio falls into.

Silence Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Silence Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-54.768	-	0)	/	111.277
	=	-0.49

Silence Therapeutics's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-18.243	-	0)	/	116.762
	=	-0.16

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.49

Silence Therapeutics (OTCPK:SLNCF) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Silence Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Silence Therapeutics (Silence Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (OTCPK:SLNCF) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

SLN:USA XRP2:Germany

Address

72 Hammersmith Road, London, GBR, W14 8TH

Website

https://www.silence-therapeutics.com

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.